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1682-606X/Copyright ª 2014, TaiwanSummary Colorectal mixed endocrine-glandular neoplasms, a subtype of neuroendocrine tu-
mors, are mainly diagnosed based on pathological characterization. The rarity and unusual
presentation of mixed endocrine tumors makes their prognosis relatively poor, and an optimal
management strategy for the tumors has yet to be devised. Here, we report a case of cecal
mixed adenocarcinoma and neuroendocrine carcinoma with ileal tumor seeding, lymph nodes,
and left iliac crest metastasis. After undergoing right hemicolectomy, target therapy, chemo-
therapy, and radiotherapy for adenocarcinoma, the patient survived for more than 15 months
and remains alive at the time of writing.
Copyright ª 2014, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Colorectal mixed endocrine-glandular neoplasms, which
are rare and heterogeneous in composition, are a type of
neuroendocrine tumor. These tumors are composed of at
least two populations and account for at least 30% of all
tumor cases.1 Because the prognosis of mixed endocrine-
glandular neoplasms of the colon and rectum is poor,
diagnosing these tumors immediately is crucial for enablinghave no conflicts of interest
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Surgical Association. Published bypatients to benefit from treatment with alternative cyto-
toxic chemotherapeutic agents.22. Case report
A 52-year-old woman with no major systemic disease was
admitted to an emergency room because of right lower
abdominal pain for 3 days. The patient history revealed
that she experienced left iliac pain for approximately 3
months and right lower abdominal pain 3 days before
entering the emergency room. In our emergency room,
epigastric tenderness was noted. Blood test results were:
white blood cell count, 11.1  109/L; neutrophils, 82.4%; C-
reactive protein, 0.37 mg/dL; glutamyl oxaloacetic trans-
aminase, 26 U/L; Na, 139 meq/L; and K, 4.3 meq/L. An X-Elsevier Taiwan LLC. All rights reserved.
Figure 1 Monotonous hyperchromatic cells with adenoid
nesting growth pattern (hematoxylin and eosin stain, 200).
Figure 3 Synaptophysin (þ) for tumor cells.
202 T.-J. Liang, T.-Y. Keray of the kidney, ureter, and bladder showed mild
increased bowel gas in the central abdomen. An abdominal
sonogram revealed the presence of ascites and suggested
diverticulitis or appendicitis. Abdominal computed tomog-
raphy revealed an irregular eccentric mass, with di-
mensions of approximately 4.3 cm  3.2 cm, in the cecum
with ileocecal valve involvement and blurring of the sur-
rounding pericolic fat plane, metastatic lymphadenopa-
thies in the mesenteric cavity and intercavo-aortic space
with the largest lymphadenopathy being approximately
1.6 cm  2.4 cm, and a suspicious osteolytic lesion in the
left iliac crest. The patient then received right hemi-
colectomy, and a polypoid tumor, approximately
6 cm  5 cm in size, was detected along with near
obstruction in the cecum, several enlarged and hard lymph
nodes in the mesenteric root, dilatation of the small in-
testine, and tumor seeding in the terminal ileum. Pathology
revealed a mixed adenocarcinoma and neuroendocrine
tumor (Fig. 1) with terminal ileum seeding and regional
lymph node metastasis (8/12), including angiolymphatic
and neural/perineural invasion. The neuroendocrine tumorFigure 2 Cytokeratin (þ) for tumor cells.was classified as G2 grade, and the adenocarcinomatous
parts were poorly differentiated. An immunohistochemical
study showed positive staining for the epidermal growth
factor receptor (1þ, 30%), cytokeratin (Fig. 2), synapto-
physin (Fig. 3), and Ki-67 (15%). The American Joint Com-
mittee on Cancer 7 staging was pT3N1M1. In addition, a
whole-body bone scan performed using technetium-99m
methylene diophosphate revealed bone metastasis
through the left anterior iliac crest to the upper aspect of
the left acetabulum. After the operation, a full course (1
course 2 weeks; 12 courses) of target therapy and chemo-
therapy using bevacizumabeFOLFIRI was administered, and
radiotherapy (3000 cGy/10 frs) was administered to the left
iliac crest. Thereafter, the patient was followed up at our
outpatient department regularly and received no
medication.3. Discussion
Neuroendocrine cells are distributed throughout the human
body, including organs such as the gastrointestinal tract,
pancreas, lung, thyroid, and adrenal glands.3 The largest
population of neuroendocrine cells is located in the
gastrointestinal tract.4 However, neuroendocrine tumors of
the colon and rectum are rare. The reported incidence of
these tumors is between 0.1% and 3.9% of all colorectal
malignancies.3
Like primary colorectal adenocarcinomas, most colo-
rectal neuroendocrine tumors are distributed in the rectum
and cecum.4,5 In addition, data showed that the frequency
of combined adenocarcinoma and neuroendocrine tumors
in the proximal colon is high.1 In accordance with previous
reports, our patient’s combined adenocarcinoma and
neuroendocrine tumor was located in the cecum. Neuro-
endocrine tumors behave aggressively and are associated
with a prognosis less favorable than that of conventional
adenocarcinomas at the same stage3; moreover, 80% of the
tumors exhibit distant metastases at the time of diagnosis.6
Similar signs were observed in our patient, who exhibited
left iliac crest metastasis and lymph node and terminal
ileum involvement at the time of diagnosis.
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sification, gastroenteropancreatic neuroendocrine tumors
are classified as well-differentiated neuroendocrine tu-
mors, well-differentiated neuroendocrine carcinomas, and
poorly-differentiated neuroendocrine carcinomas (small
cell carcinomas).7 However, in 2010, the World Health Or-
ganization reclassified gastroenteropancreatic neuroendo-
crine tumors into neuroendocrine tumors G1, G2, and G3
(large cell type or small cell type). Among these categories,
only G3 is neuroendocrine carcinoma.8
The systematic application of immunohistochemical
techniques to the study of tumors has led to the recognition
that neuroendocrine cells occur rather frequently in
exocrine neoplasms of the gut. The spectrum of combina-
tions of exocrine and neuroendocrine components is wide,
ranging from adenomas or carcinomas with interspersed
neuroendocrine cells at one extreme to classical neuroen-
docrine tumors with a focal exocrine component at the
other extreme. In addition, both exocrine and neuroendo-
crine components can have different morphological fea-
tures, The features of exocrine components range from
adenomas to adenocarcinomas differentiated to various
degrees, and the features of neuroendocrine components
range from well-differentiated to poorly-differentiated
neuroendocrine tumors.9 Usually, the neuroendocrine
component is well-differentiated, and it is easily recog-
nized based on its clear histological features and verified by
performing immunodetection by using specific neuroendo-
crine markers, including chromogranin, synaptophysin,
neuron-specific enolase, prostatic acid phosphatase, so-
matostatin, 5-HT, Ki67, and CD56.1,3 However, if the
neuroendocrine component is poorly differentiated, then
the demonstration of neuroendocrine markers is required
to confirm the diagnosis.9 Because endocrine cells are often
inconspicuous and their quantity is not substantial, the
diagnosis is made only after the tumors are stained with
neuroendocrine cell markers.1 Our patient had positive
neuroendocrine markers, including synaptophysin and Ki67.
Although a wide range of combinations of neuroendo-
crine and exocrine components are frequently observed in
routine practice, mixed exocrineeneuroendocrine carci-
nomas, recently renamed mixed adenoneuroendocrine
carcinomas (MANECs), are rare. By definition, this type of
neoplasms contains the two components, each representing
at least 30% of the lesion.9 The patient in this report rep-
resented a case of mixed adenocarcinoma and neuroendo-
crine tumor G2, which may also be described as a mixed
adenocarcinomaeneuroendocrine tumor (MANET) or MANEC
containing a well- differentiated neuroendocrine tumor
component according to a previous study.9
Because of the rarity and unusual presentation of MAN-
ECs and MANETs, an optimal strategy for managing these
tumors has yet to be devised. A previous study recom-
mended that extrapulmonary neuroendocrine carcinomas,
particularly small-cell carcinomas of the colon and rectum,
be treated with cytotoxic chemotherapeutic regimens
similar to those used for small-cell carcinoma of the lung.4
In a small-scale serial trial evaluating the treatment of
metastatic anaplastic neuroendocrine carcinomas of the
colon and rectum, the combination of cisplatin andetoposide was associated with a 67% response rate and a
median survival of 19 months.4 However, the efficacy of this
chemotherapy regimen in treating colorectal neuroendo-
crine carcinomas has yet to be validated. According to the
literature, the median survival period for patients with
neuroendocrine carcinomas of the colon and rectum is
5e11 months,3 and 1-year survival rates have been re-
ported to be 10e15%.3 Generally, the more aggressive
component of MANECs must be considered before deter-
mining a treatment regimen for these patients. It has been
suggested that mixed tumors containing a well-
differentiated neuroendocrine component and an adeno-
carcinoma component should be treated in a manner
similar to that used to treat adenocarcinoma. MANECs
containing a poorly-differentiated neuroendocrine compo-
nent must be treated as poorly-differentiated neuroendo-
crine carcinomas.10 Our patient had a mixed
neuroendocrine tumor (G2) and poorly differentiated
adenocarcinoma of the cecum with left iliac crest metas-
tasis and lymph node and terminal ileum involvement.
Therefore, she was treated as if she had colorectal
adenocarcinoma with bone metastasis. After undergoing
target therapy using bevacizumab (Avastin), chemotherapy
using FOLFIRI, and radiotherapy of the left iliac crest, she
has survived for more than 15 months.References
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